Pallas Capital Advisors LLC Raises Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)

Pallas Capital Advisors LLC increased its holdings in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 113.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 47,649 shares of the biotechnology company's stock after buying an additional 25,322 shares during the quarter. Pallas Capital Advisors LLC's holdings in Exelixis were worth $1,759,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Coppell Advisory Solutions LLC acquired a new stake in shares of Exelixis during the 4th quarter worth approximately $25,000. Colonial Trust Co SC grew its stake in shares of Exelixis by 616.9% during the 4th quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 765 shares during the period. Principal Securities Inc. grew its stake in shares of Exelixis by 62.8% during the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company's stock worth $32,000 after purchasing an additional 373 shares during the period. Kestra Investment Management LLC acquired a new stake in shares of Exelixis during the 4th quarter worth approximately $39,000. Finally, Crowley Wealth Management Inc. acquired a new stake in shares of Exelixis during the 4th quarter worth approximately $50,000. Institutional investors and hedge funds own 85.27% of the company's stock.

Insider Buying and Selling at Exelixis

In other news, EVP Dana Aftab sold 1,508 shares of Exelixis stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $39.00, for a total transaction of $58,812.00. Following the transaction, the executive vice president now owns 693,181 shares in the company, valued at $27,034,059. The trade was a 0.22% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Christopher J. Senner sold 100,000 shares of Exelixis stock in a transaction on Friday, May 16th. The stock was sold at an average price of $46.00, for a total value of $4,600,000.00. Following the transaction, the chief financial officer now owns 967,842 shares in the company, valued at approximately $44,520,732. This represents a 9.36% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 458,113 shares of company stock worth $21,024,817. Corporate insiders own 2.82% of the company's stock.

Exelixis Trading Down 0.5%

EXEL stock traded down $0.19 during midday trading on Friday, reaching $41.59. The stock had a trading volume of 2,132,163 shares, compared to its average volume of 2,355,332. The company's fifty day simple moving average is $39.69 and its 200 day simple moving average is $36.86. The company has a market cap of $11.34 billion, a price-to-earnings ratio of 23.50, a price-to-earnings-growth ratio of 1.13 and a beta of 0.28. Exelixis, Inc. has a 52-week low of $21.36 and a 52-week high of $48.85.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. Wells Fargo & Company reaffirmed a "market outperform" rating on shares of Exelixis in a research note on Thursday, April 17th. UBS Group reissued an "underperform" rating on shares of Exelixis in a research note on Thursday, April 17th. Citigroup lifted their price target on shares of Exelixis from $45.00 to $56.00 and gave the company a "buy" rating in a research note on Thursday, May 15th. HC Wainwright lifted their price target on shares of Exelixis from $40.00 to $47.00 and gave the company a "buy" rating in a research note on Thursday. Finally, Bank of America lifted their price target on shares of Exelixis from $45.00 to $46.00 and gave the company a "neutral" rating in a research note on Thursday, June 5th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $39.76.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.